透視港股通丨美團再獲超5億加倉
北水總結
4月26日港股市場,北水成交淨賣出0.9億,其中港股通(滬)成交淨賣出1.35億港元,港股通(深)成交淨買入2.25億港元。
北水淨買入最多的個股是美團-W(03690)、中海油(00883)、復星醫藥(02196)。北水淨賣出最多的個股是建設銀行(00939)、中國電信(00728)、騰訊(00700)。

數據來源:盈立智投APP
十大成交活躍股

港股通(滬)十大活躍成交股

港股通(深)十大活躍成交股
數據來源:港交所
個股點評
科網股現分化,美團-W(03690)、快手-W(02015)分別獲淨買入5.16億、1.08億港元,而騰訊(00700)遭淨賣出8272萬港元。消息面上,大和近日發表報告表示,自3月下旬以來疫情反覆,爲互聯網行業帶來了波動影響,有跡象表明對遊戲行業的監管有所放鬆,預計內地科網行業2022年增長放緩但利潤率會有所提高。該行重申對中國互聯網行業“正面”評級。
中海油(00883)獲淨買入1.87億港元。消息面上,大摩近日發佈研報,將今年的石油需求增長預期從每天340萬桶下調至每天270萬桶。在短期內,市場正在應對經濟增長的低迷和美國大量釋放石油戰略儲備的影響。但大摩將對全球基準布倫特原油的第三和第四季度價格預測上調了10美元/桶,因俄羅斯和伊朗造成的供應缺口超出預期。大摩表示,儘管石油市場存在短期需求阻力,但供應問題的影響更大。
復星醫藥(02196)獲淨買入1.54億港元。消息面上,據媒體報道,國藥集團中國生物奧密克戎變異株新冠病毒滅活疫苗獲中國國家藥監局臨牀批件;科興控股生物技術有限公司基於奧密克戎研製的新冠病毒滅活疫苗也獲得中國藥監局臨牀批件。市場憧憬復必泰疫苗獲批,據悉,復星國際執行董事、聯席CEO陳啓宇此前表示,由復星醫藥和德國BioNTech合作開發的mRNA新冠疫苗復必泰,在內地上市的審批註冊工作仍在積極溝通中。
招商銀行(03968)獲淨買入1.32億港元。消息面上,摩根大通發表報告稱,招商銀行有提供量化財務指引穩定市場信心,而且對於提名王良爲行長能否被政府批準仍然是隱憂,相信會繼續影響股價,但招行股價昨日調整了10.3%,相信進一步下跌空間有限。該行維持予招行“增持”評級,目標價85港元。
李寧(02331)獲淨買入1.13億港元。消息面上,申萬宏源香港發佈研報稱,國內服飾市場近期明顯回暖,雖然疫情反覆對人民消費意欲有一定影響,但服飾行業仍保持不俗表現,疫情時期的在線銷售影響也較少。該行表示,外圍關稅豁免預期利好出口業務,後疫情時期帶起的運動需求及市場佔比的重塑均反映國內體育服裝品牌基本面穩步成長,市場景氣向上趨頭明確。
舜宇光學(02382)獲淨買入6186萬港元。消息面上,據媒體報道,業內人士透露,由於iPhone 13系列銷售強勁,蘋果將第二季度iPhone 13 Pro系列總生產目標上調1000萬部。其中,iPhone13 Pro規劃產量從原先的100萬部增加至700萬部以上;iPhone 13 Pro Max規劃產量從原先的300萬部增加至約600萬部。
中國電信(00728)遭淨賣出1.93億港元。消息面上,瑞信發表報告稱,中國移動(00941)和中國電信首季純利差過該行預期分別7%和6%,而中國聯通(00762)在非經營項目影響下,首季純利則勝該行預期10%。報告稱,整體行業服務收入首季按年增長9.5%,符合該行早前預期,隨著電訊公司正在進行科技轉型和發展工業互聯網業務,EBITDA利潤率壓力繼續存在,並且可能會持續一兩年。
此外,藥明生物(02269)、理想汽車-W(02015)、海吉亞醫療(06078)分別獲淨買入3650萬、2888萬、845萬港元。而建設銀行(00939)遭淨賣出1.96億港元。
港股通最新持股比例排行

(港股通持股比例排行,交易所數據T+2日結算)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.